Mark S. MD Gelder

Mark S. MD Gelder, listed as senior executive, appears in our data through filings on Traws Pharma, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 28 September 2021 to 7 February 2023, the count stands at 3 filings.

Every open-market trade on record is a purchase: 1 purchase worth €8,557, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 2 option exercises.

Most recently, on 8 February 2023, the filings show an option exercise in Traws Pharma, Inc. The clock since the last published purchase (29 September 2021) now reads 1,845 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.